Åsa Kornfeld
Direttore/Membro del Consiglio presso ARCEDE PHARMA AB
Provenienza dei contatti di primo grado di Åsa Kornfeld
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Aptahem AB
 Aptahem AB Pharmaceuticals: MajorHealth Technology Aptahem AB operates as a biotechnology company. The firm engages in developing drug candidates for the treatment and prevention of disease caused by blockages in blood vessels as the result of blood clots, such as deep vein thrombosis, stroke and heart failure. Its main business model is to clinically develop aptamer-based treatments for life-threatening acute conditions where coagulation and inflammation interact in the disease process. The company was founded byLuiza Jedlina, Bert Junno, Tina Persson and Johan Lindh in 2014 and is headquartered in Malmo, Sweden.
11
| Public Company | Pharmaceuticals: Major | 11 |
| Public Company | Medical Distributors | 10 | |
| Public Company | Pharmaceuticals: Major | 6 | |
| Public Company | Miscellaneous Commercial Services | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Åsa Kornfeld tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| TAURUS ENERGY AB | Oil & Gas Production | Director/Board Member | |
| AQUA BIO TECHNOLOGY ASA | Chemicals: Major Diversified | Director/Board Member | |
| University of Pennsylvania | College/University | Undergraduate Degree | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal | |
Reiten & Co. AS
 Reiten & Co. AS Investment ManagersFinance Reiten & Co. AS (Reiten) is an independent private equity firm headquartered in Oslo, Norway. The company was founded in 1992 by Narve Reiten, the firm launched their private equity business in 1996. Reiten manages a number of private equity investment funds such as Nordic Capital Partners I, II, III, IV and Reiten & Co. Capital Partners V, VI, VII. | Investment Managers | Founder Private Equity Investor | |
| University of Uppsala | College/University | Graduate Degree Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Graduate Degree | |
| University of Stockholm | College/University | Corporate Officer/Principal Graduate Degree | |
| WEIFA ASA | Pharmaceuticals: Major | Chief Executive Officer Chief Executive Officer | |
| University of Lund | College/University | Director/Board Member Doctorate Degree Graduate Degree | |
| Vrije Universiteit Brussel | College/University | Doctorate Degree | |
| Danmarks Farmaceutiske Universitet | College/University | Doctorate Degree | |
Grilstad Holding AS
 Grilstad Holding AS Food: Meat/Fish/DairyConsumer Non-Durables Grilstad Holding AS is a holding company that is engaged in the acquisition, production, and trade of meat products. Its activities include slaughtering, butchering, and processing of meat. The firm supplies its commodities to groceries and foodservice throughout Norway. The company was founded on January 3, 2007 and is headquartered in Ranheim, Norway. | Food: Meat/Fish/Dairy | Director/Board Member Director/Board Member | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Gothenburg | College/University | Doctorate Degree Doctorate Degree | |
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Founder | |
| WNTRESEARCH AB | Pharmaceuticals: Other | Chief Executive Officer | |
| SERODUS ASA | Biotechnology | Director/Board Member Director/Board Member | |
| LIDDS AB | Pharmaceuticals: Major | Director/Board Member | |
Forskarpatent i Syd AB
 Forskarpatent i Syd AB Miscellaneous Commercial ServicesCommercial Services Forskarpatent i Syd AB specialises in the commercialisation, through licensing or new venture spinouts, of patentable inventions emanating mainly from Swedish universities. It holds a portfolio of projects in the format of shares in spinouts, partnered (licensed) and still unpartnered assets. It is involves in projects in pharmaceutical, technology, and food categories. The firm is categorized under patent agency operations. The company was founded on January 18, 1996 and is headquartered in Lund, Sweden. | Miscellaneous Commercial Services | Chief Executive Officer | |
| Balx 4 AB | Director/Board Member | ||
| Cardio Vax LLC | Director/Board Member | ||
| Jakten 7 AB | Director/Board Member | ||
PheroNet AB
 PheroNet AB Chemicals: AgriculturalProcess Industries PheroNet AB provides lures for insect monitoring. It offers insect pheromones for pest management, pheromone traps to detect harmful insect species in a crop, and synthetic pheromones for mating disruptions. Its products include adoxophyes orana, anarsia lineatella, bonagota cranaodes, cydia pomonella, cydia splendana, eupoecilia ambiguella, grapholita funebrana, grapholita lobarzewskii grapholita molesta, lobesia botrana, pammene rhediella, pandemis heparana, sparganothis pilleriana and spilonota ocellana. The company is headquartered in Alnarp, Sweden. | Chemicals: Agricultural | Chief Executive Officer | |
| Jotunfjell AS | Director/Board Member | ||
| Magnus Innovasjon AS | Chief Executive Officer | ||
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Founder | |
| Ideonfonden AB | Director/Board Member Chief Executive Officer | ||
| Accequa AB | Chairman Founder | ||
| COMBIGENE AB | Pharmaceuticals: Major | Chairman | |
| EMPLICURE AB (PUBL) | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| CYXONE AB | Pharmaceuticals: Major | Founder Director/Board Member Director/Board Member Chief Executive Officer | |
Farma Investment AS
 Farma Investment AS Real Estate Investment TrustsFinance Farma Investment AS invests in shares and real properties. The company was founded on June 23, 2011 and is headquartered in Oslo, Norway. | Real Estate Investment Trusts | Chairman | |
| Biovotec A/S | Director/Board Member | ||
| Ff Bygg Og Vedlikehold AS | Director/Board Member | ||
Langseth Advokatfirma DA
 Langseth Advokatfirma DA Miscellaneous Commercial ServicesCommercial Services Langseth Advokatfirma Da is a law firm based in Oslo that offers legal advice and procedure assistance to private individuals and companies. The firm has a team of talented lawyers with extensive experience in dispute resolution, including in court if necessary. One of the main focus areas of the firm is cabin and leisure adjustments, in addition to common legal issues related to real estate. The subject group is led by lawyers with extensive experience in this area. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Navamedic AS
 Navamedic AS Pharmaceuticals: MajorHealth Technology Novicus Pharma AS engages in pharmaceutical business. The firm is a pharmaceutical company focusing on OTC products for the Norwegian and Nordic market. The company is headquartered in Oslo, Norway. | Pharmaceuticals: Major | Chief Operating Officer Founder Corporate Officer/Principal | |
| OBSERVE MEDICAL ASA | Electronic Equipment/Instruments | Chief Executive Officer Chairman Director/Board Member | |
| Lead Discovery Malaysia Sdn. Bhd. | Chief Executive Officer | ||
| Galecto Biotech AB | Founder Founder | ||
| Accequa GmbH | Director/Board Member Director/Board Member | ||
| Noviga Research AB | Founder | ||
| Nova Law Firm | Corporate Officer/Principal | ||
| Gabather Finans AB | Director/Board Member | ||
Advokatfirmaet Nova Da
 Advokatfirmaet Nova Da Miscellaneous Commercial ServicesCommercial Services Advokatfirmaet Nova Da is a medium-sized law firm based in Oslo, Norway with additional offices in Volda and Bodø. The firm has been providing high-quality legal assistance since 1995 and offers a free case evaluation. Nova prides itself on its innovative approach while maintaining a strong foundation of expertise and experience. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Mylifeproducts AS | Chairman | ||
| QUESTBACK GROUP | Packaged Software | Chairman Director/Board Member | |
Melius Pharma AB
 Melius Pharma AB Pharmaceuticals: MajorHealth Technology Melius Pharma AB is a Swedish clinical stage pharmaceutical company that develops new treatments for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. The company is based in Lund, Sweden and is privately owned, benefiting from the support of two of Sweden's most prominent professional life science investors who bring expertise to develop the company. IPF is a chronic, progressive lung inflammation characterized by fibrosis and disruption of normal lung architecture. Melius Pharma has developed ME-015, which stabilizes ion channels in the neuronal endings in the lungs that mediate cough. ME-015 is presumed to have an acute effect and is a solution for chronic cough, which is one of the major symptoms experienced by 80%% of IPF patients. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| SENSIDOSE AB | Electronic Equipment/Instruments | Director/Board Member Director/Board Member Director/Board Member Chairman Director of Finance/CFO |
Statistiche
Distribuzione geografica
| Svezia | 24 |
| Norvegia | 19 |
| Danimarca | 5 |
| Stati Uniti | 3 |
| Belgio | 2 |
Settori
| Health Technology | 14 |
| Consumer Services | 8 |
| Commercial Services | 5 |
| Process Industries | 3 |
| Finance | 3 |
Posizioni
| Director/Board Member | 125 |
| Chairman | 49 |
| Corporate Officer/Principal | 35 |
| Founder | 26 |
| Chief Executive Officer | 22 |
Contatti più connessi
- Borsa valori
- Insiders
- Åsa Kornfeld
- Connessioni Società
